| Similar Articles |
|---|
 |
Pharmaceutical Executive
April 10, 2014
Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated?   |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Bio-IT World
May 19, 2004
Barbara Depompa |
Turning Sugar into Science The landmark building that housed the New England Confectionery Company in Revere, Mass. is being transformed into the new headquarters for the Novartis Institutes for BioMedical Research. |
National Real Estate Investor
June 1, 2003
H. Lee Murphy |
Who's Behind Biotech? There is a niche in the office market where vacancies are a fraction of the national rate, rents are way above average, and prospects for growth actually exist. It is the specialized (and regionally concentrated) business of supplying space to the biotech and life sciences industry. |
CFO
December 1, 2006
Kate O'Sullivan |
Biotech Dreaming Cities and states in the U.S. are vying to become biotechnology hot spots. Ultimately, some regions may not have enough of the key ingredients for biotech success. |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Job Journal
July 15, 2007
Rich Heintz |
Solano County Fast-growing Solano County offers affordable living and jobs aplenty. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
IndustryWeek
November 1, 2002
Tonya Vinas |
Questioning Biotech's Benefits While most communities are investing to attract or grow biotechnology companies, a recent report concludes that only a handful of cities will benefit in the long run. |
Commercial Investment Real Estate
May/Jun 2005
Bell & Drummond |
Biotech Boom Biotech tenants have specific needs for lab/office space, but they do not need a physical link to a city's business center. In addition to biotech, the nanotech and biopharmaceutical industries are also growing quickly. |
Bio-IT World
June 15, 2003
Bob Violino |
Mid-Atlantic/Southeast Region Maryland: Making a Federal Case for Biotechnology... Puerto Rico: Isle of Incentives... Virginia: Planting Needed Seed Capital... North Carolina: Triangulating Biotech Resources... Florida: Shining Resources on Small Biotech Sector |
Bio-IT World
June 15, 2003
Barbara Depompa |
Southwest Region Texas: Bioscience with a Space Spin... New Mexico: Building a Bioinformatics Niche... Arizona: Focus on Cancer and Neurological Therapy... Southern California: Deep Biotech Roots Grow Many Branches... Northern California: 'Can You Afford To Be Elsewhere?'... |
National Real Estate Investor
May 1, 2006
F. R. Skinner |
Bulking Up On Biotech Investing in the development of a highly unique, medical-grade building is only going to appeal to a select niche of investors. But with biotech returns averaging some 1% to 2% higher than the general office market, it is a smart play for investors wanting a diversified portfolio. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Chemistry World
October 28, 2014
Phillip Broadwith |
Amgen stacks up additional job cuts US biotech heavyweight Amgen is to cut an extra 600 -- 1100 jobs by the end of 2015, on top of the 2900 the company earmarked for the chop in August. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
National Real Estate Investor
February 1, 2007
Morris Newman |
Biotech Clouds Don't Obscure San Diego's Sunny Future Nothing in life is perfect, but the suburban office markets of San Diego County have little to complain about at present in spite of the tepid biotech sector, once the crown jewel of the area's economy. |
The Motley Fool
June 29, 2005
Karl Thiel |
Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success. |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Entrepreneur
January 2008
Aliza Pilar Sherman |
The Boys' Club Although the situation is improving, there are still far fewer women entrepreneurs than men in the fast-growing biotech field. |
Job Journal
September 21, 2003
Marty Nemko |
Biotech = Opportunity What this strong growth industry could offer you |
Pharmaceutical Executive
September 1, 2008
Zhu Shen |
Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. |
The Motley Fool
February 23, 2005
Brian Gorman |
Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
Bio-IT World
June 15, 2003
Melissa Kruse |
Midwest/South Region Ohio: Outpacing U.S. in Bioscience Growth... Alabama: Sweet Home to Tech Tax Incentives... Kentucky: Investing Multimillions to Breed Bio Business... Minnesota: The 'Right Mix' of Talent and Funding... Tennessee: Pioneering Research Centers... Michigan: Teeming 'Life Sciences Corridor'... etc. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
BusinessWeek
June 13, 2005 |
Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Bio-IT World
April 2006
Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed. |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006... |
Fast Company
November 1, 2007
Tinker Ready |
Drug Flow and Deal Flow The news at this year's Biotech Investing confab will focus on Big Pharma companies, as they take a more active role in developing early-stage drugs. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
Bio-IT World
May 2006
Mark D. Uehling |
Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape? |
HBS Working Knowledge
December 8, 2003
Sean Silverthorne |
Why Europe Lags in Pharmaceuticals and Biotech Governmental, cultural and academic differences are hurting Europe's chances of gaining on the U.S. Can anything be done? |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
The Motley Fool
December 15, 2004
Brian Gorman |
Korea's Biotech Bet Korea's new facility could stimulate biotech research in Asia and lower costs for biotech companies. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
The Motley Fool
February 28, 2011
David Williamson |
Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
June 25, 2007
Brian Orelli |
Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note. |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
BusinessWeek
January 12, 2004 |
Biotech: A Comeback "Balanced On A Razor's Edge" Skeptical investors want to see products that get to market and add to the bottom line. |
